Published in Eur Respir J on April 02, 2015
TOLLIP, MUC5B, and the Response to N-Acetylcysteine among Individuals with Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med (2015) 0.95
Re-evaluation of diagnostic parameters is crucial for obtaining accurate data on idiopathic pulmonary fibrosis. BMC Pulm Med (2015) 0.88
Impact of Comorbidities on Mortality in Patients with Idiopathic Pulmonary Fibrosis. PLoS One (2016) 0.84
Pulmonary Hypertension in Patients with Chronic Fibrosing Idiopathic Interstitial Pneumonias. PLoS One (2015) 0.83
Effect of Nintedanib in Subgroups of Idiopathic Pulmonary Fibrosis by Diagnostic Criteria. Am J Respir Crit Care Med (2016) 0.81
Exploring Clinical and Epidemiological Characteristics of Interstitial Lung Diseases: Rationale, Aims, and Design of a Nationwide Prospective Registry-The EXCITING-ILD Registry. Biomed Res Int (2015) 0.75
Insights into idiopathic pulmonary fibrosis in the real world. Eur Respir J (2015) 0.75
What patients with pulmonary fibrosis and their partners think: a live, educative survey in the Netherlands and Germany. ERJ Open Res (2017) 0.75
Effect of statins on disease-related outcomes in patients with idiopathic pulmonary fibrosis. Thorax (2016) 0.75
Utility of Transbronchial versus Surgical Lung Biopsy in the Diagnosis of Suspected Fibrotic Interstitial Lung Disease. Chest (2016) 0.75
Body mass index-percent forced vital capacity-respiratory hospitalization: new staging for idiopathic pulmonary fibrosis patients. J Thorac Dis (2016) 0.75
Burden of Idiopathic Pulmonary Fibrosis Progression: A 5-Year Longitudinal Follow-Up Study. PLoS One (2017) 0.75
Idiopathic Pulmonary Fibrosis: Diagnosis and Clinical Manifestations. Clin Med Insights Circ Respir Pulm Med (2016) 0.75
Health related quality of life in patients with idiopathic pulmonary fibrosis in clinical practice: insights-IPF registry. Respir Res (2017) 0.75
An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med (2011) 22.39
Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. Eur Respir J Suppl (1993) 20.55
American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS). Am J Respir Crit Care Med (2000) 12.71
Reference spirometric values using techniques and equipment that meet ATS recommendations. Am Rev Respir Dis (1981) 10.89
Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med (2014) 10.62
A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med (2014) 9.40
Multi-ethnic reference values for spirometry for the 3-95-yr age range: the global lung function 2012 equations. Eur Respir J (2012) 7.18
An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med (2013) 6.82
Bias. J Epidemiol Community Health (2004) 3.85
Cryptogenic fibrosing alveolitis: clinical features and their influence on survival. Thorax (1980) 3.70
A comparison of the assessment of quality of life with CAT, CCQ, and SGRQ in COPD patients participating in pulmonary rehabilitation. COPD (2012) 2.60
A multidimensional index and staging system for idiopathic pulmonary fibrosis. Ann Intern Med (2012) 2.54
Velcro crackles: the key for early diagnosis of idiopathic pulmonary fibrosis? Eur Respir J (2012) 2.22
The SF-36 and SGRQ: validity and first look at minimum important differences in IPF. Respir Med (2009) 2.18
Minimally clinically important difference for the UCSD Shortness of Breath Questionnaire, Borg Scale, and Visual Analog Scale. COPD (2005) 2.14
Influence of secular trends and sample size on reference equations for lung function tests. Eur Respir J (2010) 1.88
Significance of bronchoalveolar lavage for the diagnosis of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med (2009) 1.88
The role of cardiac registries in evidence-based medicine. Eur Heart J (2010) 1.83
Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med (2014) 1.80
Future directions in idiopathic pulmonary fibrosis research. An NHLBI workshop report. Am J Respir Crit Care Med (2014) 1.54
Challenges in pulmonary fibrosis: 8--The need for an international registry for idiopathic pulmonary fibrosis. Thorax (2008) 1.48
Minimal clinically important difference for the UCSD Shortness of Breath Questionnaire. J Cardiopulm Rehabil (2005) 1.47
Assessment of current practice in the diagnosis and therapy of idiopathic pulmonary fibrosis. Respir Med (2008) 1.37
Guidelines for good pharmacoepidemiology practices (GPP). Pharmacoepidemiol Drug Saf (2005) 1.20
Are data from clinical registries of any value? Eur Heart J (2000) 1.10
Patient experiences with pulmonary fibrosis. Respir Med (2006) 1.07
Idiopathic pulmonary fibrosis: guidelines for diagnosis and clinical management have advanced from consensus-based in 2000 to evidence-based in 2011. Eur Respir J (2011) 1.03
Pharmacological treatment of idiopathic pulmonary fibrosis: from the past to the future. Eur Respir Rev (2013) 1.02
Triple therapy in idiopathic pulmonary fibrosis: an alarming press release. Eur Respir J (2012) 1.00
Investigating significant health trends in idiopathic pulmonary fibrosis (INSIGHTS-IPF): rationale, aims and design of a nationwide prospective registry. BMJ Open Respir Res (2014) 0.89
A global registry for idiopathic pulmonary fibrosis: the time is now. Eur Respir J (2014) 0.88
Management of idiopathic pulmonary fibrosis in France: a survey of 1244 pulmonologists. Respir Med (2013) 0.83